Both PC3-PSMA/Vec and /KLK4 cells had the same baseline bioluminescence, as demonstrated by in vitro imaging of the cell lines prior to injection (Figure S2), confirming the difference in in vivo tumor bioluminescence is indeed due to a difference in tumor burden. The gene discussed is FOLH1; the disease is neoplasm.